Longeveron (LGVN)

• Market cap: $26.3M
• 1 day: 7.27%
• 5 days: -1.67%
• 1 month: -9.69%
• 3 months: -11.50%
• 6 months: -7.81%
• Year to date: -86.59%
• 1 year: -87.88%
• 5 years: -97.61%
• 10 years: -97.61%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Employees: 24

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

4% less capital invested

Capital invested by funds: $536K [Q2] → $512K (-$24.1K) [Q3]

4.78% less ownership

Funds ownership: 6.83% [Q2] → 2.05% (-4.78%) [Q3]

10% less funds holding

Funds holding: 21 [Q2] → 19 (-2) [Q3]

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 465% upside
• Avg. target: $10 465% upside
• High target: $10 465% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Roth MKM Boobalan Pachaiyappan 0% 1-year accuracy 0 / 4 met price target	465% upside $10	Buy Initiated	5 Dec 2024
HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 117 / 313 met price target	465% upside $10	Buy Reiterated	25 Nov 2024